Post by dnr08 on Apr 29, 2021 11:51:43 GMT
I'm just starting to read the transcript. First observation: "In addition, we are also generally pleased with the advancement of opko's pharmaceutical businesses." Really Steve? You then go on to say two things: 1) Pfizer is doing a great job shepherding hGH through the worldwide regulatory process, and 2) your in-house Rayaldee sales force continues to sell very little Rayaldee.
So, your partners are doing their job well, while Opko continues to fall short. Is this 33% drop in YOY sales for Q1 sales of your only drug typical of most drugs across the pharma universe?*
I mean, the guy has been regurgitating the same script about hGH for 18 months, word for word. And for Rayaldee, reports over the past year have also been the same, just changing the numbers to reflect larger DECLINES in sales. Then, hilariously, he actually says that they're training "salespeople" in "virtual selling techniques"...to mitigate the effects of the pandemic? Just getting around to that now Steve? Fantastic job.
* I just glanced at Eli Lilly's YOY results for 11 drugs. Only 3 products had sales declines: -3%,-10%,-12%. The other eight had GAINS in sales compared the Q1 2020: 1%, 5%, 6%, 8%, 9%, 15%, 33%, and > 100% (that was Reblozyl, which went from $8 million to $112 million). I guess LLY has figured out a way to grow sales, and not experiencing what's happening at Opko, where "As in recent quarters, the Rayaldee sales force continues to contend with the impact of COVID-19 on in-person access to physicians, as well as a decline in patient visits to physicians' offices."
So, your partners are doing their job well, while Opko continues to fall short. Is this 33% drop in YOY sales for Q1 sales of your only drug typical of most drugs across the pharma universe?*
I mean, the guy has been regurgitating the same script about hGH for 18 months, word for word. And for Rayaldee, reports over the past year have also been the same, just changing the numbers to reflect larger DECLINES in sales. Then, hilariously, he actually says that they're training "salespeople" in "virtual selling techniques"...to mitigate the effects of the pandemic? Just getting around to that now Steve? Fantastic job.
* I just glanced at Eli Lilly's YOY results for 11 drugs. Only 3 products had sales declines: -3%,-10%,-12%. The other eight had GAINS in sales compared the Q1 2020: 1%, 5%, 6%, 8%, 9%, 15%, 33%, and > 100% (that was Reblozyl, which went from $8 million to $112 million). I guess LLY has figured out a way to grow sales, and not experiencing what's happening at Opko, where "As in recent quarters, the Rayaldee sales force continues to contend with the impact of COVID-19 on in-person access to physicians, as well as a decline in patient visits to physicians' offices."